Combination Product Development
— Pre-filled Syringe and Injection Devices

Patty H. Kiang, Ph.D.
Kiang Consultant Services
PattyKiang1@Yahoo.com
WCCPDA Dinner Meeting
August 18, 2016
Agenda

• Introduction
• Market trends
• FDA Combination Product Regulations
• CGMP requirements for Combination products
  - Design Control
  - Human Factors & Usability study
• Primary container compatibility issue
What is Combination product?

- Under 21 CFR 3.2 (e): A combination product is a product composed of any combination of drug/device; biological product/device; drug/biological product; or drug/device/biological product.

- **Single entity combination products**: A product comprised of two or more regulated components that are physically, chemically, or otherwise combined or mixed and produced as a single entity; examples: prefilled syringe, pen injector.
What is Combination product?

• **Co-packaged combination products**: Two or more separate products packaged together in a single package or as a unit and comprised of drug + device products, device + biological products, or biological + drug products; examples: drug + syringe + needle

• **Cross-labeled combination products**: A drug, device or biological product packaged separately that according to its proposed labeling is intended for use only with an approved individually specified drug, device or biological product; examples: photosensitizing drug x activating laser light source.
Market Trends

• Prefilled syringes and injection devices are gaining strong acceptance as delivery systems for injectable drugs.

• The main use of the delivery system is for treatment of chronic conditions requiring patients to self-administer medication.

• Interest in combination products is high due to opportunities they offer to enhance product safety and efficacy.
Prefilled syringe & injection devices market growth

Prefilled Syringes

Historical Demand and Forecast Worldwide Growth*

- Prefilled Devices
- Prefilled Device Growth

Year-on-Year Growth, Percent

Billions of Units**

<table>
<thead>
<tr>
<th>Year</th>
<th>Prefilled Devices</th>
<th>Prefilled Device Growth</th>
</tr>
</thead>
<tbody>
<tr>
<td>2006</td>
<td>1.57</td>
<td>13.2%</td>
</tr>
<tr>
<td>2007</td>
<td>1.72</td>
<td>13.4%</td>
</tr>
<tr>
<td>2008</td>
<td>1.95</td>
<td>14.4%</td>
</tr>
<tr>
<td>2009</td>
<td>2.23</td>
<td>10.0%</td>
</tr>
<tr>
<td>2010</td>
<td>2.52</td>
<td>21.0%</td>
</tr>
<tr>
<td>2011</td>
<td>2.84</td>
<td>16.0%</td>
</tr>
<tr>
<td>2012</td>
<td>3.18</td>
<td>10.0%</td>
</tr>
<tr>
<td>2013</td>
<td>3.55</td>
<td>11.0%</td>
</tr>
<tr>
<td>2014</td>
<td>3.94</td>
<td>10.4%</td>
</tr>
<tr>
<td>2015</td>
<td>4.35</td>
<td>11.0%</td>
</tr>
</tbody>
</table>

** Units are traditional PFS, Disposable Injectors or Pen Cartridges
* Includes non-therapeutic medical applications (e.g., sterile saline, contrast agents, etc.)

Source: Greystone Prefilled Syringe Report, April 2011

kiang consultant services
Market Trends

• The combination products provide:
  – Ease of use
  – Reduced drug waste
  – Patient centric design
  – Customization
  – Market differentiation

• The global Prefilled syringe market is likely to achieve sales of USD 6.9 BN by 2018, growing at a compounded annual growth rate of 13.8% from 2012 to 2018*.

* Pre-filled Syringe Market, 2013-2023, Roots Analysis, business research & consulting.
Prefilled Syringe & Needle Safety Device (OSHA regulation)
Amgen: Enbrel auto injector

http://www.enbrel.com
Schering Plough/Merck: Dual chamber injector
- Large volume sub-q
- High viscosity
- Cartridge based
FDA Combination Products Regulation

• FDA ‘s office of combination products is an organizational component in the office of the commissioner; its role is to facilitate and coordinate consistent FDA regulation of combination products.

• A combination product can be formed in three ways, through integration, co-packaging and labeling.

• FDA can apply whatever regulatory resources it deems necessary to assure the safety and effectiveness of a combination product; this produces developmental and regulatory complexity.
Jurisdiction of Combination products

• Single entity Combination product:
  – Drug (or biologic): Primary Mode of Action
  – CDER (or CBER): Primary Jurisdiction
  – CDRH: Consultation

• Co-packaged or Kit Combination product:
  – Drug (or biologic): Primary Mode of Action
  – CDER (or CBER): Primary Jurisdiction
    • Device may already be regulated by CDRH as a general use device (needs specific use labeling)
  – CDRH: Consultation
Quality Regulations for Combination Products

• Quality Regulations:
  – Drug & Biologic cGMP
    • 21CFR 210, 211
    • 21CFR 600 through 680
  – Quality system Regulation (QSR, Device cGMP)
    • 21CFR820
  – CGMP Requirements for Combination Products
    • 21CFR4
• Draft Guidance for Industry and FDA Staff: Current Good Manufacturing Requirements for Combination Products (2015)
CGMP for Combination Products

- For a combination with drug and device constituent parts, must be compliant with both CGMP and QSR
- A drug CGMP Quality System based **Streamlining Approach** 21CFR4.4(b)(1)
  - 21CFR 820.20  Management responsibility
  - **21CFR 820.30**  Design Control
  - 21CFR 820.50  Purchasing Control
  - 21CFR 820.100 Corrective and preventive action
  - 21CFR 820.170 Installation
  - 21CFR 820.200 Servicing
CGMP for Combination Products

- A QS regulation based **Streamlining Approach** 21CFR4.4(b)(2)
  - 21CFR211.84 Testing and approval or rejection of components, drug product containers and closures
  - 21CFR211.103 Calculation of yield
  - 21CFR211.137 Expiration dating
  - 21CFR211.165 Testing and release for distribution
  - 21CFR211.166 Stability testing
  - 21CFR211.167 Special testing requirements
  - 21CFR211.170 Reserve samples
Convergence in Regulatory Approach

Medical Devices (delivery device)

QSR  
Design Controls 820.30  
Risk Management ICH Q9  
Pharmaceutical Quality System ICH Q10

Drugs/ Biologics

cGMPs  
Pharmaceutical Development ICH Q8  
Risk Management ICH Q9  
Pharmaceutical Quality System ICH Q10
### Device Development – follow Design Control Process

<table>
<thead>
<tr>
<th>Stage 1: Initiation</th>
<th>Stage 2: Planning</th>
<th>Stage 3: Development</th>
<th>Stage 4: Production</th>
<th>Stage 5: Commercialization</th>
</tr>
</thead>
<tbody>
<tr>
<td>Market Assessment</td>
<td>Create Device Team</td>
<td>Create /evaluate Prototypes</td>
<td>Transfer Design</td>
<td>Launch Product</td>
</tr>
<tr>
<td>Assess Device value</td>
<td>Initiate Design History File</td>
<td>Design Review &amp; Risk Analysis</td>
<td>Commission Facility</td>
<td>Manage Supply Chain</td>
</tr>
<tr>
<td>Technical Assessment</td>
<td>Define Design Inputs</td>
<td>Design Verification</td>
<td>Design &amp; Process Validation</td>
<td>Conduct Post-Market Surveillance</td>
</tr>
<tr>
<td>Propose Device Attributes</td>
<td>Initiate partner/ CMO selection</td>
<td>Create Device Master Record</td>
<td>Complete Device Master Record</td>
<td>Manage CAPA &amp; Complaints</td>
</tr>
<tr>
<td>Assess Regulatory Landscape</td>
<td>Conduct CMO Risk Assessments</td>
<td>Finalize Quality &amp; Supply Agreements</td>
<td>Submit Regulatory Package</td>
<td>Identify Process Improvements</td>
</tr>
<tr>
<td>Develop Marketing Required Document</td>
<td>Create Device Development Plan</td>
<td>Human factors Usability study</td>
<td>Draft Complaints &amp; CAPA Plan</td>
<td>Final Review</td>
</tr>
</tbody>
</table>

*kiang consultant services*
FDA Regulations Relevant to Human Factors

- Quality System regulation: 21 CFR 820.30, **Design Controls** – need for human factors is implied:
  - **Design input** – includes “needs of the user and patient”
  - **Design verification** – performance criteria met
  - **Design validation** – “… devices conform to defined user needs and intended uses and shall include testing of production units under actual or simulated use conditions. Design validation shall include software validation and risk analysis….” [incl. **use-related risks**]

*Molly Follette Story, PhD FDA /CDRH / ODE, RAPS Webinar June 7, 2012*
Primary container compatibility issues

- J & J Eprex: leachables from uncoated syringe plungers
- Silicone oil causing protein aggregation
- Uneven coated silicone oil causing incomplete injection
- Leachable substances from staked needle causing drug degradation
- Sterility issue due to seal integrity problem
Thanks for your attention

- Dr. Anthony Andre will discuss Human factors and usability
- Dr. Wei Liu will discuss Primary container closure compatibility issue